API | dalpiciclib

dalpiciclib Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Now

Chemistry

SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
InChIKey: SGJLSPUSUBJWHO-UHFFFAOYSA-N
Mol. Mass: 446.56
ALogP: 4.02 Partition coefficient
ChEMBL Molecule:
dalpiciclib

More Chemistry

Pharmacology

Mechanisms of Action:
- Cyclin-dependent kinase 4 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 6 (Homo sapiens) ^UniProt
- Estrogen receptor (Homo sapiens) ^UniProt
- Estrogen receptor beta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

shr6390

Organizations (26)

Research & Development (26)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)

Breast Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 1)

Melanoma (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Sezary Syndrome (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 67
# of Trial Organizations: 26

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue